SENTICOL III
Tests whether removing only the first draining lymph nodes is safe enough to spare women the lymphoedema of full node removal.
Non-inferiority trial (~950 patients) with disease-free survival and quality of life endpoints, following the SENTICOL I/II accuracy studies and the SENTIX single-arm trial. Readout expected 2027-28.
Setting
Early-stage cervical cancer: sentinel lymph node biopsy alone vs sentinel node plus full pelvic lymphadenectomy
Phase
Phase 3
Sponsor
ARCAGY-GINECO / ENGOT
Registry